AINOSTICS secures $2,600,000
We have just secured approximately $2,600,000 in funding to accelerate the development of our ground-breaking technologies for performing diagnosis and outcome prognosis in neurological conditions, such as dementia.
According to our CEO, Dr Hojjat Azadbakht: "this funding will be used to conduct pilot studies in a number of clinical sites in the UK and accelerate our NHS adoption strategy. It will also significantly de-risk the already unique proposition offered by AINOSTICS for future investors".
A big thank you to our fantastic team at AINOSTICS for their continued hard work, and to all our advisors and partners for sharing our vision.
More details to be revealed in the near future.